Article
Intrapatient Molecular and Histologic Heterogeneity After First-generation or Second-generation TKI Therapy of NSCLC Patients: Potential Clinical Impact on Subsequent third-generation TKI Treatment.
American journal of clinical oncology - 1 Nov 2019
Iacono Daniela, Osman Giorgia A, Migliorino Maria R, Grillo Lucia, Remotti Daniele, Nunnari Josè, Ricciardi Serena, Rossi Antonio, Mancuso Andrea, Graziano Paolo, Di Lorenzo Angela, Bronzini Monica, Signora Mauro, Leone Alvaro
Abstract excerpt
OBJECTIVES: The discovery of tyrosine kinase inhibitors (TKI) has remarkably improved the clinical course of patients with non-small cell lung cancer driven by Epidermal Growth Factor Receptor (EGFR) mutations. However, virtually in all cases, the disease resurfaces in a TKI-resistant form that is mainly linked to an acquired EGFR-T790M mutation, a MET amplification, or small cell lung cancer (SCLC)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.